Summary: DOACs were associated with a lower risk of recurrent VTE in patients ≥100 to <120 kg compared to warfarin.
Outcomes* Unadjusted† Adjusted†,‡
HR 95% CI P value HR 95% CI P value
Recurrent VTE            
≥140 kg 1.24 0.56-2.76 .60 1.31 0.59-2.98 .52
≥120 to <140 kg 0.71 0.40-1.23 .22 0.69 0.39-1.21 .19
≥100 to <120 kg 0.65 0.46-0.91 .01 0.69 0.48-0.98 .04
≥60 to <100 kg 0.84 0.67-1.05 .13 0.90 0.72-1.14 .38
<60 kg 1.29 0.47-3.57 .62 1.22 0.44-3.41 .70
1|2|3|4|5|6|7|8|9|10|11|12